Six versus four or five cycles of first‐line etoposide and platinum‐based chemotherapy combined with thoracic radiotherapy in patients with limited‐stage small‐cell lung cancer: A propensity score‐matched analysis of a prospective randomized trial

Six versus four or five cycles of first‐line etoposide and platinum‐based chemotherapy combined with thoracic radiotherapy in patients with limited‐stage small‐cell lung cancer: A propensity score‐matched analysis of a prospective randomized trial

Abstract Objectives The recommended treatment for limited‐stage small‐cell lung cancer (LS‐SCLC) is a combination of thoracic radiotherapy (TRT) and etoposide plus cisplatin (EP) chemotherapy, typically administered over 4–6 cycles. Nonetheless, the optimal duration of chemotherapy is still not dete...

Full description

Bibliographic Details
Main Authors: Tian‐tian Yu, Xiao Hu, Wei‐jian Liufu, Shao‐qing Niu, Hui‐min Lian, Hong‐lian Ma, Jin Wang, Yong Bao, Ming Chen, Fang Peng
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Cancer Medicine
Subjects:
chemotherapy
concurrent chemoradiotherapy
cycles of chemotherapy
limited‐stage SCLC
radiotherapy
Online Access:https://doi.org/10.1002/cam4.7215

Internet

https://doi.org/10.1002/cam4.7215

Similar Items